Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B ...

Hepatitis B virus infections can progress from an acute ... % base pairing to form an unbranched rod-like structure. The genome sequence shows no homology to the 3300-nucleotide genome of a ...

HBV mutant types were also tested by direct sequencing for 1619 participants with serum HBV DNA levels ≥ 10 000 copies/mL. As shown in Figure 1, there were 4155 HBsAg-seropositive and 19 665 ...

the ARCUS nuclease specifically cuts a highly conserved sequence in the hepatitis B viral genome and is designed to eliminate cccDNA and inactivate integrated HBV genomes. The ARCUS platform is ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

detecting DNA sequences, carrying out DNA fingerprinting, forensic analysis, and molecular cloning, diagnosing genetic diseases, and detecting pathogens such as Hepatitis B and C viruses ...

When the mRNA is expressed in HBV-infected hepatocytes, it cuts a sequence in the HBV genome that is designed to eliminate cccDNA in vivo. With this approach, the company hopes to stop HBV from ...

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

- Expected cash runway into the second half of 2026 with sufficient capital to phase 1 clinical data for multiple in vivo gene editing programs - Company to host virtual investor event ...